KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Share-based Compensation (2016 - 2025)

Quest Diagnostics' Share-based Compensation history spans 17 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 7.41% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $88.0 million, changed 0.0%, while the annual FY2025 figure was $88.0 million, 0.0% changed from the prior year.
  • Share-based Compensation for Q4 2025 was $25.0 million at Quest Diagnostics, up from $20.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $27.0 million in Q4 2024 and bottomed at $16.0 million in Q2 2023.
  • The 5-year median for Share-based Compensation is $20.0 million (2024), against an average of $20.4 million.
  • The largest annual shift saw Share-based Compensation crashed 44.12% in 2021 before it surged 42.11% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $19.0 million in 2021, then rose by 15.79% to $22.0 million in 2022, then dropped by 13.64% to $19.0 million in 2023, then soared by 42.11% to $27.0 million in 2024, then dropped by 7.41% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Share-based Compensation are $25.0 million (Q4 2025), $20.0 million (Q3 2025), and $21.0 million (Q2 2025).